OsteoarthritisPhase 3NCT01089725
Efficacy And Safety Study Of Tanezumab Subcutaneous Administration In Osteoarthritis - A Subcutaneous/Intravenous Bridging Study
A Phase 3 study testing Tanezumab SC and Tanezumab IV in people with Osteoarthritis and Arthritis, run by Pfizer at 91 sites in United States.
Trial summary
This is an efficacy and safety study of 3 doses (2.5 mg, 5 mg and 10mg) of tanezumab administered subcutaneously versus placebo. This study will also compare a subcutaneous (SC) administration of 10 mg of tanezumab) with an intravenous (IV) administration of 10 mg of tanezumab. Read more about this study
- Who is it for?
- Ages 18 to 99 years
- Conditions the study is for
- Osteoarthritis, Arthritis, Pain
- What is being tested?
- Tanezumab SC and Tanezumab IV
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 385 participants
- Where
- 91 sitesUnited States
- Study dates
- 30 Mar 2010to 18 Feb 2011
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 99 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Diagnosis of osteoarthritis (OA) of the knee according to American College of Rheumatology (ACR) criteria with a Kellgren- Lawrence score of greater than or equal to 2
- 18 years of age or greater
- Two methods of birth control one of which must be barrier if of childbearing potential
- Willing to discontinue pain medication except as permitted per protocol
Who cannot join
- Pregnancy or wishing to be pregnant during the course of the study, lactating women
- Body Mass Index (BMI) greater than 39
- Clinically significant cardiac, neurological, psychiatric conditions and other conditions that are excluded by the protocol.
- Previous exposure to a Nerve Growth Factor (NGF) antibody
Trial locations and contacts
91 sites in 1 country.
91 sites in 1 country
United States91 sites
Advanced Clinical Research Institute
Anaheim, California, 92801
West Coast Radiology Center
Anaheim, California, 92801
Ann Arbor Clinical Reserch
Ann Arbor, Michigan, 48103
FutureSearch Trials of Neurology
Austin, Texas, 78731
Tekton Research, Inc.
Austin, Texas, 78745
Tekton Research, Inc
Austin, Texas, 78745
Billings Clinic Infusion Center
Billings, Montana, 59101
Billings Clinic Research Center
Billings, Montana, 59101
Sonoma Clinical Research, LLC.
Boise, Idaho, 83702
Sonora Clinical Research
Boise, Idaho, 83702
Beacon Clinical Research, LLC
Brockton, Massachusetts, 02301
Providence Clinical Research
Burbank, California, 91505
PMG Research of Charlotte
Charlotte, North Carolina, 28209-3734
Charlottesville Medical Research
Charlottesville, Virginia, 22911
Apex Medical Research, AMR, Inc.
Chicago, Illinois, 60616
Community Research
Cincinnati, Ohio, 45245
Sterling Research Group, Ltd.
Cincinnati, Ohio, 45246
Mountain State Clinical Research
Clarksburg, West Virginia, 26301
Innovative Research of West Florida, Inc.
Clearwater, Florida, 33756
Nature Coast Clinical Research
Crystal River, Florida, 34429
Altoona Center for Clinical Research
Duncansville, Pennsylvania, 16635
Colorado Hematology
Englewood, Colorado, 80110
Colorado Orthopedic Consultants, P.C.
Englewood, Colorado, 80110
Fleming Island Center for Clinical Research
Fleming Island, Florida, 32003
Arthritis Treatment Center
Frederick, Maryland, 21702
Valley Research
Fresno, California, 93720
Greensboro Imaging
Greensboro, North Carolina, 27407
Pharmquest
Greensboro, North Carolina, 27408
Arthritis Associates, PLLC
Hattiesburg, Mississippi, 39402
East-West Medical Research Institute
Honolulu, Hawaii, 96814
Westbury Medical Clinic
Houston, Texas, 77005
Asif Cochinwala, MD, P.A.
Houston, Texas, 77008
Accurate Clinical Research
Houston, Texas, 77034
Mercury Clinical Research
Houston, Texas, 77036
Pioneer Research Solutions, Inc
Houston, Texas, 77036
Clinical Trial Network
Houston, Texas, 77074
Houston Institute for Clinical Research
Houston, Texas, 77074
Little York Medical Center
Houston, Texas, 77093
Westside Center for Clinical Research
Jacksonville, Florida, 32205
Jacksonville Center for Clinical Research
Jacksonville, Florida, 32216
SoFHA Clinical Research
Johnson City, Tennessee, 37604
Internist Associates of Texas
Kingwood, Texas, 77339
Allergy and Rheumatology Medical Clinic, Inc.
La Jolla, California, 92037-1233
Triwest Research Associates
La Mesa, California, 91942
BayCare Outpatient Imaging at Bardmoor
Largo, Florida, 33777
G. Timothy Kelly, MD
Las Vegas, Nevada, 89128
Lebanon Internal Medicine Associates
Lebanon, Pennsylvania, 17042
Bluegrass Community Research, Inc.
Lexington, Kentucky, 40504
Physician Research Collaboration, LLC
Lincoln, Nebraska, 68516
Novara Clinical Research
Mesa, Arizona, 85206
BenchMark Research
Metairie, Louisiana, 70006
Vaughn H. Mancha, Jr., MD, PC
Montgomery, Alabama, 36117
Coastal Carolina Research Center
Mt. Pleasant, South Carolina, 29464
Accurate Clinical Research Inc
Nassau Bay, Texas, 77058
Synergy Clinical Research Center
National City, California, 91950
LION Research
Norman, Oklahoma, 73069
McBride Clinic
Norman, Oklahoma, 73072
Health Research Institute
Oklahoma City, Oklahoma, 73109
Midwest Minor Medical
Omaha, Nebraska, 68114
Quality Clinical Research, Inc.
Omaha, Nebraska, 68114
Midwest Minor Medical
Omaha, Nebraska, 68127
Midwest Minor Medical
Omaha, Nebraska, 68144
Sunshine Research Center
Opa-locka, Florida, 33054
Founders Research Corporation
Philadelphia, Pennsylvania, 19152
Redpoint Research
Phoenix, Arizona, 85029
DMI Research, Inc.
Pinellas Park, Florida, 33782
Clinical Investigations of Texas, LLC
Plano, Texas, 75075
Wake Internal Medicine Consultants, Inc.
Raleigh, North Carolina, 27612
Wake Research Associates, LLC
Raleigh, North Carolina, 27612
Health Concepts
Rapid City, South Dakota, 57702
Hypothe Test, LLC
Roanoke, Virginia, 24018
Andrew Porges, MD, PC
Roslyn, New York, 11576
Benchmark Research
Sacramento, California, 95816
Benchmark Research
San Angelo, Texas, 76904
Probe Clinical Research Corp.
Santa Ana, California, 92701
Trinity Clinical Trials
Santa Ana, California, 92701
St. Petersburg Arthritis Center
St. Petersburg, Florida, 33710
Stamford Therapeutics Consortium
Stamford, Connecticut, 06905
Pioneer Research Solutions, Inc
Sugar Land, Texas, 77479
Troy Internal Medicine, PC
Troy, Michigan, 48098
FMC Clinical Trials
Upland, California, 91786
Office of Cynthia Morgan, MD
Washington D.C., District of Columbia, 20003
Advanced Clinical Research
West Jordan, Utah, 84088
The Center for Rheumatology and Bone Research
Wheaton, Maryland, 20902
Professional Research Network of Kansas, LLC
Wichita, Kansas, 67203
Wichita Clinic PA
Wichita, Kansas, 67208
Grayline Clinical Drug Trials
Wichita Falls, Texas, 76309
North Georgia Clinical Research
Woodstock, Georgia, 30189
North Georgia Internal Medicine
Woodstock, Georgia, 30189
Clinical Pharmacology Study Group
Worcester, Massachusetts, 01610
Clinical Research Center of Reading, LLP
Wyomissing, Pennsylvania, 19610
About this study
Official title: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB IN PATIENTS WITH OSTEOARTHRITIS OF THE KNEE.
This is an efficacy and safety study of 3 doses (2.5 mg, 5 mg and 10mg) of tanezumab administered subcutaneously versus placebo. This study will also compare a subcutaneous (SC) administration of 10 mg of tanezumab) with an intravenous (IV) administration of 10 mg of tanezumab. Each person will receive an IV infusion and a SC infusion. The study will last 16 weeks for those who wish to enter a 64-week extension study or 24 weeks for those who do not.
Read the detailed description
This study was terminated on 08 Nov 2010 following a US FDA clinical hold for tanezumab osteoarthritis clinical studies which halted dosing and enrollment of patients on 23 June 2010 for potential safety issues.
- Conditions
- Osteoarthritis, Arthritis, Pain
- Being tested
- Placebo IV, Placebo SC, Tanezumab SC, Tanezumab IV
- Keywords
- safety, efficacy, parallel group, double-blind, multicenter, injection, infusion, osteoarthritis, bridging, subcutaneous, intravenous, tanezumab
- Medical subject headings
- Osteoarthritis, Arthritis, Pain
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Placebo IVBiological
1 ml of placebo administered SC and IV once every 8 weeks.
Placebo SCBiological
1 ml of placebo administered SC and IV once every 8 weeks.
Tanezumab SCBiological
1 ml tanezumab injection SC administered every 8 weeks
Placebo IVBiological
1 ml placebo administered IV every 8 weeks
Tanezumab SCBiological
1 ml tanezumab injection SC administered every 8 weeks
Placebo IVBiological
1ml placebo administered IV every 8 weeks
Tanezumab SCBiological
1 ml tanezumab injection SC administered every 8 weeks
Placebo IVBiological
1ml placebo administered IV every 8 weeks
Tanezumab IVBiological
1 ml tanezumab injection IV administered every 8 weeks
Placebo SCBiological
1ml placebo administered SC every 8 weeks
| Study group | Role | What they receive |
|---|---|---|
| Placebo | Placebo comparator | Not described Receives: Biological: Placebo IV; Biological: Placebo SC |
| 2.5 mg tanezumab SC and placebo IV | Experimental | Not described Receives: Biological: Tanezumab SC; Biological: Placebo IV |
| 5 mg tanezumab SC and placebo IV | Experimental | Not described Receives: Biological: Tanezumab SC; Biological: Placebo IV |
| 10 mg tanezumab SC and placebo IV | Experimental | Not described Receives: Biological: Tanezumab SC; Biological: Placebo IV |
| 10 mg tanezumab IV | Experimental | Not described Receives: Biological: Tanezumab IV; Biological: Placebo SC |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score at Week 16
The WOMAC pain subscale is a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis in the index knee in the past 48 hours. It is calculated as the mean of the scores from the 5 individual questions scored on a numerical rating scale (NRS) of 0 to 10, where higher scores indicate higher pain. Total score range for WOMAC pain subscale score is 0 to 10, where higher scores indicate higher pain.
Measured: Baseline, Week 16
Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale Score at Week 16
The WOMAC physical function subscale is a 17-item questionnaire used to assess the degree of difficulty experienced due to osteoarthritis in the index joint in the past 48 hours. It is calculated as the mean of the scores from the 17 individual questions scored on a NRS of 0 to 10, where higher scores indicate worse function. Total score range for WOMAC physical function subscale score is 0 to 10, where higher scores indicate worse function.
Measured: Baseline, Week 16
Change From Baseline in Patient's Global Assessment (PGA) of Osteoarthritis Score at Week 16
Participants answered the question: "Considering all the ways your osteoarthritis in your knee affects you, how are you doing today?" Participants responded by using a 5-point scale where 1 = very good (asymptomatic and no limitation of normal activities), 2 = good (mild symptoms and no limitation of normal activities), 3 = fair (moderate symptoms and limitation of some normal activities), 4 = poor (severe symptoms and inability to carry out most normal activities) and 5 = very poor (very severe symptoms which are intolerable and inability to carry out all normal activities). Higher score indicated severe condition.
Measured: Baseline, Week 16
Secondary outcomes (18)
Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale at Weeks 1, 2, 4, 8, and 12
The WOMAC pain subscale is a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis in the index knee in the past 48 hours. It is calculated as the mean of the scores from the 5 individual questions scored on a numerical rating scale (NRS) of 0 to 10, where higher scores indicate higher pain. Total score range for WOMAC pain subscale score is 0 to 10, where higher scores indicate higher pain.
Measured: Baseline, Weeks 1, 2, 4, 8, and 12
Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale at Weeks 1, 2, 4, 8, and 12
The WOMAC physical function subscale is a 17-item questionnaire used to assess the degree of difficulty experienced due to osteoarthritis in the index joint in the past 48 hours. It is calculated as the mean of the scores from the 17 individual questions scored on a NRS of 0 to 10, where higher scores indicate worse function. Total score range for WOMAC physical function subscale score is 0 to 10, where higher scores indicate worse function.
Measured: Baseline, Weeks 1, 2, 4, 8, and 12
Change From Baseline in Patient Global Assessment (PGA) of Osteoarthritis at Weeks 1, 2, 4, 8, and 12
Participants answered the question: "Considering all the ways your osteoarthritis in your knee affects you, how are you doing today?" Participants responded by using a 5-point scale where 1 = very good (asymptomatic and no limitation of normal activities), 2 = good (mild symptoms and no limitation of normal activities), 3 = fair (moderate symptoms and limitation of some normal activities), 4 = poor (severe symptoms and inability to carry out most normal activities) and 5 = very poor (very severe symptoms which are intolerable and inability to carry out all normal activities). Higher score indicated severe condition.
Measured: Baseline, Weeks 1, 2, 4, 8, and 12
Percentage of Participants With Outcome Measures in Rheumatology - Osteoarthritis Research Society International (OMERACT-OARSI) Response
The OMERACT-OARSI responder index is based on 3 parameters. OMERACT-OARSI response: greater than or equal to (>=) 50 percent (%) improvement from baseline and absolute change from baseline of >=2 units at week of interest in WOMAC pain or physical function subscale, or at least 2 of the following 3 being true: >=20% improvement from baseline and absolute change from baseline of >=1 unit at week of interest in 1) WOMAC pain subscale, 2) WOMAC physical function subscale, 3) PGA of osteoarthritis (score range: 1-5, higher score=more affected). WOMAC pain, physical function subscales assess amount of pain/difficulty experienced (score range: 0-10, higher score=higher pain/difficulty).
Measured: Weeks 1, 2, 4, 8, 12, and 16
Percentage of Participants With at Least 30%, 50%, 70% and 90% Reduction From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score
The WOMAC pain subscale is a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis in the index knee in the past 48 hours. It is calculated as the mean of the scores from the 5 individual questions scored on a numerical rating scale (NRS) of 0 to 10, where higher scores indicate higher pain. Total score range for WOMAC pain subscale score is 0 to 10, where higher scores indicate higher pain.
Measured: Weeks 1, 2, 4, 8, 12, and 16
Number of Participants With Cumulative Reduction From Baseline in Western Ontario and McMaster Universities Osteoarthritis (WOMAC) Pain Subscale Score at Weeks 1, 2, 4, 8, 12, and 16
The WOMAC pain subscale is a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis in the index knee in the past 48 hours. It is calculated as the mean of the scores from the 5 individual questions scored on a NRS of 0 to 10, where higher scores indicate higher pain. Total score range for WOMAC pain subscale score is 0 to 10, where higher scores indicate higher pain. Participants with specified reduction (as percent) from baseline at Week 16 are reported.
Measured: Weeks 1, 2, 4, 8, 12, 16
Number of Participants With Improvement of at Least 2 Points in Patient's Global Assessment (PGA) of Osteoarthritis
Participants answered the question: "Considering all the ways your osteoarthritis in your knee affects you, how are you doing today?" Participants responded by using a 5-point scale where 1 = very good (asymptomatic and no limitation of normal activities), 2 = good (mild symptoms and no limitation of normal activities), 3 = fair (moderate symptoms and limitation of some normal activities), 4 = poor (severe symptoms and inability to carry out most normal activities) and 5 = very poor (very severe symptoms which are intolerable and inability to carry out all normal activities). Higher score indicated severe condition. Improvement signifies a decrease of at least 2 points on the 5-point scale relative to baseline value.
Measured: Weeks 1, 2, 4, 8, 12, and 16
Change From Baseline in Average Pain Score in the Index Knee at Weeks 1, 2, 4, 8, 12 and 16
Participants assessed average osteoarthritis pain in their knee in the past 24 hours on an 11-point NRS ranging from 0 (no pain) to 10 (worst pain). Higher score indicated greater pain. Baseline score was calculated as the mean of the scores over the 3 days in the initial pain assessment period and a weekly mean was calculated using the daily pain scores within each study week.
Measured: Baseline, Weeks 1, 2, 4, 8, 12, and 16
Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Stiffness Subscale Score at Weeks 1, 2, 4, 8, 12, and 16
The WOMAC stiffness subscale is a 2-item questionnaire used to assess the amount of stiffness experienced in the index joint in the past 48 hours. It is calculated as the mean of the scores from the 2 individual questions scored on NRS of 0 to 10, with higher scores indicating more stiffness. Total score range for WOMAC stiffness subscale score is 0 to 10, where higher scores indicate more stiffness. Stiffness is defined as a sensation of decreased ease in movement of the knee.
Measured: Baseline, Weeks 1, 2, 4, 8, 12, and 16
Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Average Score at Weeks 1, 2, 4, 8, 12, and 16
WOMAC: self-administered, disease-specific 24-item questionnaire, which assesses clinically important, participant-relevant symptoms for pain (5 items), stiffness (2 items) and physical function (17 items) in participants with osteoarthritis of knee. WOMAC average score is the mean of WOMAC pain, physical function and stiffness subscale scores. WOMAC pain, physical function and stiffness subscale and average score ranges from 0 to 10, where higher score indicates worse response.
Measured: Baseline, Weeks 1, 2, 4, 8, 12, and 16
Change From Baseline For Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Item: Pain When Walking on a Flat Surface at Weeks 1, 2, 4, 8, 12, and 16
Participants answered: "How much pain have you had when walking on a flat surface?" Participants responded by using a NRS of 0 to 10, where 0 = no pain and 10 = extreme pain. Higher score indicated greater pain.
Measured: Baseline, Weeks 1, 2, 4, 8, 12, and 16
Change From Baseline For Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Item: Pain When Going Up or Down Stairs at Weeks 1, 2, 4, 8, 12, and 16
Participants answered: "How much pain have you had when going up or down stairs?" Participants responded by using a NRS of 0 to 10, where 0 = no pain and 10 = extreme pain. Higher score indicated greater pain.
Measured: Baseline, Weeks 1, 2, 4, 8, 12, and 16
Change From Baseline in 36-Item Short-Form Health Survey Version 2 (SF-36v2) Domain Scores at Week 16
SF-36v2 is a standardized self-administered survey evaluating 8 aspects/domains of functional health and well-being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. The total score for each domain is scaled 0-100 (100 = highest level of functioning).
Measured: Baseline, Week 16
Change From Baseline in 36-Item Short-Form Health Survey Version 2 (SF-36v2) Physical and Mental Component Scores at Week 16
SF-36v2: standardized self-administered survey evaluating 8 aspects of functional health and wellbeing (physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health). Total score for each aspect were scaled 0-100 (100=highest level of functioning). For obtaining physical and mental component scores, z-score for each scale=(observed score - mean score for general 1990 United States [US] population)/corresponding standard deviation. The 2 component scores were obtained by multiplying each aspect z-score by physical or mental factor score coefficient (1990 general US population) and summing the eight products. Component scores indicated how many standard deviations higher (in case of positive z-score [better functioning])/lower (in case of negative z-score [worse functioning]) participant's value was relative to the mean of the reference population.
Measured: Baseline, Week 16
Time to Discontinuation Due to Lack of Efficacy
Median time to discontinuation due to lack of efficacy for participants who discontinued due to lack of efficacy was reported.
Measured: Baseline up to Week 24
Percentage of Participants Who Used Rescue Medication
In case of inadequate pain relief for osteoarthritis, acetaminophen up to 3000 mg per day up to 3 days per week could be taken as rescue medication. Incidence of rescue medication use is calculated as any use of rescue medication during the study week in question.
Measured: Weeks 1, 2, 4, 8, 12, and 16
Duration of Rescue Medication Use
In case of inadequate pain relief for osteoarthritis, acetaminophen up to 3000 mg per day up to 3 days per week could be taken as rescue medication. Duration of rescue medication use is calculated as the number of study days per week when any rescue medication was taken.
Measured: Weeks 1, 2, 4, 8, 12, and 16
Amount of Rescue Medication Taken
In case of inadequate pain relief for osteoarthritis, acetaminophen up to 3000 mg per day up to 3 days per week could be taken as rescue medication. The amount of rescue medication taken is the total dose (in mg) of acetaminophen rescue medication over the study week in question.
Measured: Weeks 1, 2, 4, 8, 12, and 16
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Mar 2010 (estimated)
- Study start30 Mar 2010
- Primary completion8 Nov 2010
- Study completion18 Feb 2011
Why it stopped: See termination reason in detailed description.
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (4)Papers the sponsor has linked to this study.
- Other trials for OsteoarthritisStudies of the same condition, open and under way.
- More trials run by PfizerThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 385 participants (actual)
Sponsor and investigators
- Lead sponsor
- Pfizer
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Pfizer CT.gov Call Center, Study director, Pfizer
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01089725
- Sponsor's protocol ID
- A4091027
- Other IDs
- SC/IV OA STUDY
- Status last verified
- Feb 2021
- First submitted
- 11 Mar 2010
- Last updated
- 5 May 2021
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
- Individual data sharing
- Yes: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical\_trials/trial\_data\_and\_results/data\_requests.
Publications
Brown MT, Cornblath DR, Koltzenburg M, Gorson KC, Hickman A, Pixton GC, Gaitonde P, Viktrup L, West CR. Peripheral Nerve Safety of Nerve Growth Factor Inhibition by Tanezumab: Pooled Analyses of Phase III Clinical Studies in Over 5000 Patients with Osteoarthritis. Clin Drug Investig. 2023 Jul;43(7):551-563. doi: 10.1007/s40261-023-01286-3. Epub 2023 Jul 18.
PubMed 37460782Berenbaum F, Schnitzer T, Kivitz A, Viktrup L, Johnston E, Yang R, Whalen E, Tive L, Semel D. Gender, age, disease severity, body mass index and diabetes may not affect response to subcutaneous tanezumab in patients with osteoarthritis after 16 weeks of treatment. A subgroup analysis of placebo-controlled trials. Int J Clin Pract. 2021 Dec;75(12):e14975. doi: 10.1111/ijcp.14975. Epub 2021 Oct 21.
PubMed 34626502Berenbaum F, Schnitzer TJ, Kivitz AJ, Viktrup L, Hickman A, Pixton G, Brown MT, Davignon I, West CR. General Safety and Tolerability of Subcutaneous Tanezumab for Osteoarthritis: A Pooled Analysis of Three Randomized, Placebo-Controlled Trials. Arthritis Care Res (Hoboken). 2022 Jun;74(6):918-928. doi: 10.1002/acr.24637. Epub 2022 Mar 25.
PubMed 33973384Tive L, Bello AE, Radin D, Schnitzer TJ, Nguyen H, Brown MT, West CR. Pooled analysis of tanezumab efficacy and safety with subgroup analyses of phase III clinical trials in patients with osteoarthritis pain of the knee or hip. J Pain Res. 2019 Mar 19;12:975-995. doi: 10.2147/JPR.S191297. eCollection 2019.
PubMed 30936738
Study at a glance
From the registry record, last updated by the sponsor on 5 May 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB IN PATIENTS WITH OSTEOARTHRITIS OF THE KNEE.
- ClinicalTrials.gov ID
- NCT01089725
- Acronym / sponsor ID
- A4091027
- Conditions
- Osteoarthritis, Arthritis, Pain
- Keywords
- safety, efficacy, parallel group, double-blind, multicenter, injection, infusion, osteoarthritis
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: See termination reason in detailed description.
- Enrolment
- 385 participants (actual)
- Lead sponsor
- PfizerIndustry (pharma, biotech, devices)
- Study start
- 30 Mar 2010 (actual)
- Primary completion
- 8 Nov 2010 (actual)
- Study completion
- 18 Feb 2011 (actual)
- First posted
- 18 Mar 2010 (estimated)
- Results
- Posted 5 May 2021
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is an efficacy and safety study of 3 doses (2.5 mg, 5 mg and 10mg) of tanezumab administered subcutaneously versus placebo. This study will also compare a subcutaneous (SC) administration of 10 mg of tanezumab) with an intravenous (IV) administration of 10 mg of tanezumab. Each person will receive an IV infusion and a SC infusion. The study will last 16 weeks for those who wish to enter a 64-week extension study or 24 weeks for those who do not.
Detailed description
This study was terminated on 08 Nov 2010 following a US FDA clinical hold for tanezumab osteoarthritis clinical studies which halted dosing and enrollment of patients on 23 June 2010 for potential safety issues.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 5
| Arm | Type | Receives |
|---|---|---|
| Placebo | Placebo comparator | Biological: Placebo IV, Biological: Placebo SC |
| 2.5 mg tanezumab SC and placebo IV | Experimental | Biological: Tanezumab SC, Biological: Placebo IV |
| 5 mg tanezumab SC and placebo IV | Experimental | Biological: Tanezumab SC, Biological: Placebo IV |
| 10 mg tanezumab SC and placebo IV | Experimental | Biological: Tanezumab SC, Biological: Placebo IV |
| 10 mg tanezumab IV | Experimental | Biological: Tanezumab IV, Biological: Placebo SC |
Who may qualify
- Ages
- 18 to 99 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Diagnosis of osteoarthritis (OA) of the knee according to American College of Rheumatology (ACR) criteria with a Kellgren- Lawrence score of greater than or equal to 2
- 18 years of age or greater
- Two methods of birth control one of which must be barrier if of childbearing potential
- Willing to discontinue pain medication except as permitted per protocol
Key exclusion criteria (4 listed)
- Pregnancy or wishing to be pregnant during the course of the study, lactating women
- Body Mass Index (BMI) greater than 39
- Clinically significant cardiac, neurological, psychiatric conditions and other conditions that are excluded by the protocol.
- Previous exposure to a Nerve Growth Factor (NGF) antibody
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Placebo IV1 ml of placebo administered SC and IV once every 8 weeks. | Biological | Placebo |
| Placebo SC1 ml of placebo administered SC and IV once every 8 weeks. | Biological | Placebo |
| Tanezumab SC1 ml tanezumab injection SC administered every 8 weeks | Biological | 2.5 mg tanezumab SC and placebo IV |
| Placebo IV1 ml placebo administered IV every 8 weeks | Biological | 2.5 mg tanezumab SC and placebo IV |
| Tanezumab SC1 ml tanezumab injection SC administered every 8 weeks | Biological | 5 mg tanezumab SC and placebo IV |
| Placebo IV1ml placebo administered IV every 8 weeks | Biological | 5 mg tanezumab SC and placebo IV |
| Tanezumab SC1 ml tanezumab injection SC administered every 8 weeks | Biological | 10 mg tanezumab SC and placebo IV |
| Placebo IV1ml placebo administered IV every 8 weeks | Biological | 10 mg tanezumab SC and placebo IV |
| Tanezumab IV1 ml tanezumab injection IV administered every 8 weeks | Biological | 10 mg tanezumab IV |
| Placebo SC1ml placebo administered SC every 8 weeks | Biological | 10 mg tanezumab IV |
Primary outcome
Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score at Week 16
Time frame: Baseline, Week 16
The WOMAC pain subscale is a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis in the index knee in the past 48 hours. It is calculated as the mean of the scores from the 5 individual questions scored on a numerical rating scale (NRS) of 0 to 10, where higher scores indicate higher pain. Total score range for WOMAC pain subscale score is 0 to 10, where higher scores indicate higher pain.
Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale Score at Week 16
Time frame: Baseline, Week 16
The WOMAC physical function subscale is a 17-item questionnaire used to assess the degree of difficulty experienced due to osteoarthritis in the index joint in the past 48 hours. It is calculated as the mean of the scores from the 17 individual questions scored on a NRS of 0 to 10, where higher scores indicate worse function. Total score range for WOMAC physical function subscale score is 0 to 10, where higher scores indicate worse function.
Change From Baseline in Patient's Global Assessment (PGA) of Osteoarthritis Score at Week 16
Time frame: Baseline, Week 16
Participants answered the question: "Considering all the ways your osteoarthritis in your knee affects you, how are you doing today?" Participants responded by using a 5-point scale where 1 = very good (asymptomatic and no limitation of normal activities), 2 = good (mild symptoms and no limitation of normal activities), 3 = fair (moderate symptoms and limitation of some normal activities), 4 = poor (severe symptoms and inability to carry out most normal activities) and 5 = very poor (very severe symptoms which are intolerable and inability to carry out all normal activities). Higher score indicated severe condition.
18 secondary outcomes
Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale at Weeks 1, 2, 4, 8, and 12
Time frame: Baseline, Weeks 1, 2, 4, 8, and 12
Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale at Weeks 1, 2, 4, 8, and 12
Time frame: Baseline, Weeks 1, 2, 4, 8, and 12
Change From Baseline in Patient Global Assessment (PGA) of Osteoarthritis at Weeks 1, 2, 4, 8, and 12
Time frame: Baseline, Weeks 1, 2, 4, 8, and 12
Percentage of Participants With Outcome Measures in Rheumatology - Osteoarthritis Research Society International (OMERACT-OARSI) Response
Time frame: Weeks 1, 2, 4, 8, 12, and 16
Percentage of Participants With at Least 30%, 50%, 70% and 90% Reduction From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score
Time frame: Weeks 1, 2, 4, 8, 12, and 16
Number of Participants With Cumulative Reduction From Baseline in Western Ontario and McMaster Universities Osteoarthritis (WOMAC) Pain Subscale Score at Weeks 1, 2, 4, 8, 12, and 16
Time frame: Weeks 1, 2, 4, 8, 12, 16
Number of Participants With Improvement of at Least 2 Points in Patient's Global Assessment (PGA) of Osteoarthritis
Time frame: Weeks 1, 2, 4, 8, 12, and 16
Change From Baseline in Average Pain Score in the Index Knee at Weeks 1, 2, 4, 8, 12 and 16
Time frame: Baseline, Weeks 1, 2, 4, 8, 12, and 16
Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Stiffness Subscale Score at Weeks 1, 2, 4, 8, 12, and 16
Time frame: Baseline, Weeks 1, 2, 4, 8, 12, and 16
Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Average Score at Weeks 1, 2, 4, 8, 12, and 16
Time frame: Baseline, Weeks 1, 2, 4, 8, 12, and 16
Change From Baseline For Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Item: Pain When Walking on a Flat Surface at Weeks 1, 2, 4, 8, 12, and 16
Time frame: Baseline, Weeks 1, 2, 4, 8, 12, and 16
Change From Baseline For Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Item: Pain When Going Up or Down Stairs at Weeks 1, 2, 4, 8, 12, and 16
Time frame: Baseline, Weeks 1, 2, 4, 8, 12, and 16
Change From Baseline in 36-Item Short-Form Health Survey Version 2 (SF-36v2) Domain Scores at Week 16
Time frame: Baseline, Week 16
Change From Baseline in 36-Item Short-Form Health Survey Version 2 (SF-36v2) Physical and Mental Component Scores at Week 16
Time frame: Baseline, Week 16
Time to Discontinuation Due to Lack of Efficacy
Time frame: Baseline up to Week 24
Percentage of Participants Who Used Rescue Medication
Time frame: Weeks 1, 2, 4, 8, 12, and 16
Duration of Rescue Medication Use
Time frame: Weeks 1, 2, 4, 8, 12, and 16
Amount of Rescue Medication Taken
Time frame: Weeks 1, 2, 4, 8, 12, and 16
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 May 2021.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 37460782Brown MT, Cornblath DR, Koltzenburg M, Gorson KC, Hickman A, Pixton GC, Gaitonde P, Viktrup L, West CR. Peripheral Nerve Safety of Nerve Growth Factor Inhibition by Tanezumab: Pooled Analyses of Phase III Clinical Studies in Over 5000 Patients with Osteoarthritis. Clin Drug Investig. 2023 Jul;43(7):551-563. doi: 10.1007/s40261-023-01286-3. Epub 2023 Jul 18.
- Derived from this study: PubMed 34626502Berenbaum F, Schnitzer T, Kivitz A, Viktrup L, Johnston E, Yang R, Whalen E, Tive L, Semel D. Gender, age, disease severity, body mass index and diabetes may not affect response to subcutaneous tanezumab in patients with osteoarthritis after 16 weeks of treatment. A subgroup analysis of placebo-controlled trials. Int J Clin Pract. 2021 Dec;75(12):e14975. doi: 10.1111/ijcp.14975. Epub 2021 Oct 21.
- Derived from this study: PubMed 33973384Berenbaum F, Schnitzer TJ, Kivitz AJ, Viktrup L, Hickman A, Pixton G, Brown MT, Davignon I, West CR. General Safety and Tolerability of Subcutaneous Tanezumab for Osteoarthritis: A Pooled Analysis of Three Randomized, Placebo-Controlled Trials. Arthritis Care Res (Hoboken). 2022 Jun;74(6):918-928. doi: 10.1002/acr.24637. Epub 2022 Mar 25.
- Derived from this study: PubMed 30936738Tive L, Bello AE, Radin D, Schnitzer TJ, Nguyen H, Brown MT, West CR. Pooled analysis of tanezumab efficacy and safety with subgroup analyses of phase III clinical trials in patients with osteoarthritis pain of the knee or hip. J Pain Res. 2019 Mar 19;12:975-995. doi: 10.2147/JPR.S191297. eCollection 2019.
- To obtain contact information for a study center near you, click here.Link provided by the sponsor.
- Individual participant dataSharing planned: Yes. Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Related trials for Osteoarthritis
Not yet recruiting
Holistic Healing for Knee Osteoarthritis
Knee Osteoarthritis (Knee OA)
Active, not recruiting
Effectiveness of Therapeutic Exercises on Spinopelvic Mobility
Osteoarthritis (OA) of the Hip
Recruiting
Effect of Anti-inflammatory Diet in Osteoarthritis
Osteoarthritis, Knee
Active, not recruitingPhase 2/3
Single vs Triple Hyaluronic Acid in Knee Osteoarthritis
Osteoarthritis, Knee
Not yet recruiting
The Feasibility of a Virtual/Home-based OA Treatment Program in Older Adults With OA and Multimorbidity
Osteoarthritis of the Knee
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Pfizer CT.gov Call Center study director
Pfizer
91 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Tanezumab SC and Tanezumab IV in people with Osteoarthritis and Arthritis, run by Pfizer at 91 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 5 May 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 91 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 5 May 2021). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score at Week 16 (time frame: Baseline, Week 16). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01089725, which also lists 4 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 May 2021.